Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Rare Diseases

Osteosarcoma

Neoplasms, Bone Tissue

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Sarcoma

Soft Tissue Sarcoma

5hmc testing

Lu Xie, M.D.

Jie Xu, M.D.

Tingting Ren, Ph. D.

Wei Guo, M.D. and Ph.D.

hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down of 5hmC-containing DNA fragments for sequencing. After selectively constructing 5hmC library, highthroughput-sequencing will be performed on an Illumina Nextseq-500 instrument. By ways of Rawdata processing, differential loci between Osteosarcoma group and control group will be detected to indentify specific epigenetic biomarkers of Osteosarcoma. From our previous trials, we identify geno sequencing related to beta-catenin pathways might have some relationship with osteosaroma primary or secondary drug resistance. Thus in this trial we try to further explore the drug resistance mechanism for advaced osteosarcoma second resistance to the combination therapy of Famitinib and Camrelizumab.

cfDNA samples were prepared from peripheral blood collected from patients. Briefly, 8 ml of peripheral blood was collected from each subject using EDTA anticoagulant tubes, and the plasma sample was prepared within 6 h by centrifuging twice at 1 350× g for 12 min, and then centrifuging at 13500× g for 12 min. The prepared plasma samples (about 2 ml/subject) were immediately stored at -80 °C. The plasma cfDNA was isolated using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's protocol.

Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

Indentifying Epigenetic Biomarkers From Peripheral Blood of Advanced Osteosarcoma Patients, Who Recieve Famitinib and Camrelizumab Based on hMe-Seal Technique

Peking University

Northwestern University

Peking University People's Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab	NCT03919539	Drug Resistance... Biomarkers for ...	5hmc testing	12 Years -	Peking University People's Hospital
Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab	NCT03919539	Drug Resistance... Biomarkers for ...	5hmc testing	12 Years -	Peking University People's Hospital

Spots Global Cancer Trial Database for 5hmc

Every month we try and update this database with for 5hmc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for 5hmc

Every month we try and update this database with for 5hmc cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for 5hmc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.